You are now leaving ThereForYou.com

Baxter Healthcare Corporation does not review or control the content of any non-Baxter site. Baxter Healthcare Corporation does not endorse and is not responsible for the accuracy, content, practices or standards of any non-Baxter sources.

About Hemophilia Hemophilia & Inhibitors

Want to Get Involved?Community Events

A handy calendar of local and national hemophilia events.

View Events

We've launchedJoin Us on Facebook

There’s More to Life Than Hemophilia

Got Questions?Get Personal Answers

Simply enter your ZIP code to connect with your Baxter representative.

Some people with hemophilia develop antibodies after they have received factor VIII concentrate. These antibodies are referred to as inhibitors.

What Is An Inhibitor?

An inhibitor is an antibody produced by the body's immune system that:

  • Identifies factor VIII concentrate as a foreign substance
  • Attacks factor VIII
  • Neutralizes factor VIII activity
  • Makes factor VIII ineffective or less effective in stopping bleeding.1

Approximately 30% of individuals with severe hemophilia A—those with factor VIII levels less than 1% of normal—develop inhibitors.2

An inhibitor can develop only after a person with hemophilia has been treated with replacement clotting factor. Most inhibitors occur early in life, usually within the first 50 days of treatment with replacement clotting factor.3

What Is The Impact Of An Inhibitor?

Patients with inhibitors do not bleed more frequently than other hemophilia patients, but their bleeds are more difficult to manage because they do not always respond to standard treatment.1

As a result, inhibitor patients have an increased risk of developing complications such as joint damage.5 Initially, a joint bleed or hemarthrosis occurs. Joint bleeding usually occurs in the knees, elbows, and ankles, and it can be very painful.4 Repeated bleeding into a joint may cause permanent joint damage, termed arthropathy, that results in a loss of normal joint function and, often, visible deformity.4

Who Is At Risk?

Anyone with hemophilia can develop an inhibitor. However, there are some factors that may increase your risk. These include:

  • Major genetic changes, called mutations, in the factor VIII gene6
  • A family history of inhibitors7
  • African heritage7
  • Hemophilia severity1

Note: ThereForYou.com does not recommend a particular treatment for specific individuals and recommends that you consult your treatment center or physician before pursuing any course of treatment.

References

  1. Kasper CK. Diagnosis and management of inhibitors to factors VIII and IX. An introductory discussion for physicians. Treatment of Hemophilia. № 34. Montréal, Canada: World Federation of Hemophilia; Sept. 2004
  2. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients: a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999; 5(3): 145-154.
  3. DiMichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia. 2002;8:280-287.
  4. Silva M, Luck JV, Jr., Llinás A. Chronic Hemophilic Synovitis: The Role Of Radiosynovectomy. Treatment of Hemophilia. No.33. Montréal, Canada: World Federation of Hemophilia; April. 2004
  5. Leissinger CA. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors. Haemophilia. 1999;5(suppl 3):25-32.
  6. Schwaab R, Brackmann HH, Meyer C, Seehafer J, Kirchgesser M, Haack A, Olek K, Tuddenham EG, Oldenburg J. Haemophilia A: mutation type determines risk of inhibitor formation. Thrombosis and Haemostasis. 1995 Dec; 74 (6): 1402-6.
  7. Astermark J, Berntorp E, White GC, Kroner BL. The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia. 2001;7:267-272.